Citalopram versus other antidepressants for depression
by ncbi.nlm.nih.gov
Major depression is a severe mental illness characterised by a persistent and unreactive low mood and loss of all interest and pleasure, usually accompanied by a range of symptoms including appetite change, sleep disturbance, fatigue, loss of energy, poor concentration, psychomotor symptoms, inappropriate guilt and morbid thoughts of death. Antidepressant drugs remain the mainstay of treatment in moderate?to?severe major depression. During the last 20 years, selective serotonin reuptake inhibitors (SSRIs) have progressively become the most commonly prescribed antidepressants. Citalopram, one of the first SSRIs introduced in the market, is the racemic mixture of S? and R?enantiomer. In the present review we assessed the evidence for the efficacy, acceptability and tolerability of citalopram in comparison with all other antidepressants in the acute?phase treatment of major depression. Thirty?seven randomised controlled trials (more than 6000 participants) were included in the present review. In terms of efficacy, citalopram was more efficacious than other reference compounds like paroxetine or reboxetine, but worse than escitalopram. In terms of side effects, citalopram was more acceptable than older antidepressants, like tricyclics. Based on these findings, we conclude that clinicians should focus on practical or clinically relevant considerations including differences in efficacy and side?effect profiles.
Abstract
Background: Recent US and UK clinical practice guidelines recommend that second?generation antidepressants should be considered amongst the best first?line options when drug therapy is indicated for a depressive episode. Systematic reviews have already highlighted some differences in efficacy between second?generation antidepressants. Citalopram, one of the first selective serotonin reuptake inhibitors (SSRI) introduced in the market, is one of these antidepressant drugs that clinicians use for routine depression care.
Objectives: To assess the evidence for the efficacy, acceptability and tolerability of citalopram in comparison with tricyclics, heterocyclics, other SSRIs and other conventional and non?conventional antidepressants in the acute?phase treatment of major depression.
Search methods: We searched The Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register and the Cochrane Central Register of Controlled Trials up to February 2012. No language restriction was applied. We contacted pharmaceutical companies and experts in this field for supplemental data.
Selection criteria: Randomised controlled trials allocating patients with major depression to citalopram versus any other antidepressants.
Data collection and analysis: Two reviewers independently extracted data. Information extracted included study characteristics, participant characteristics, intervention details and outcome measures in terms of efficacy (the number of patients who responded or remitted), patient acceptability (the number of patients who failed to complete the study) and tolerability (side?effects).
Main results: Thirty?seven trials compared citalopram with other antidepressants (such as tricyclics, heterocyclics, SSRIs and other antidepressants, either conventional ones, such as mirtazapine, venlafaxine and reboxetine, or non?conventional, like hypericum). Citalopram was shown to be significantly less effective than escitalopram in achieving acute response (odds ratio (OR) 1.47, 95% confidence interval (CI) 1.08 to 2.02), but more effective than paroxetine (OR 0.65, 95% CI 0.44 to 0.96) and reboxetine (OR 0.63, 95% CI 0.43 to 0.91). Significantly fewer patients allocated to citalopram withdrew from trials due to adverse events compared with patients allocated to tricyclics (OR 0.54, 95% CI 0.38 to 0.78) and fewer patients allocated to citalopram reported at least one side effect than reboxetine or venlafaxine (OR 0.64, 95% CI 0.42 to 0.97 and OR 0.46, 95% CI 0.24 to 0.88, respectively).
Authors' conclusions: Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy, tolerability and acceptability. Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics, reboxetine and venlafaxine, however, it seemed to be less efficacious than escitalopram. As with most systematic reviews in psychopharmacology, the potential for overestimation of treatment effect due to sponsorship bias and publication bias should be borne in mind when interpreting review findings. Economic analyses were not reported in the included studies, however, cost effectiveness information is needed in the field of antidepressant trials.
Source: https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0047318/
Friday, May 15, 2026
Sitagliptin (Januvia) - Diabetes - Patient guide
Sitagliptin, marketed as Januvia, belongs to the dipeptidyl peptidase-4 inhibitor class, commonly referred to as DPP-4 inhibitors or gliptins. This medication works by blocking the enzyme DPP-4, which normally breaks down incretin hormones including glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. When DPP-4 is inhibited, incretin hormone levels remain elevated for longer after meals, leading to increased glucose-dependent insulin secretion and reduced glucagon release from the pancreas. The glucose-dependent nature of incretins is what makes sitagliptin relatively safe from a hypoglycemia standpoint when used alone. Because incretins only stimulate insulin secretion when glucose levels are elevated, the risk of insulin overshoot and resulting low blood sugar is substantially lower than with sulfonylureas or insulin. This safety profile makes sitagliptin an attractive option for older patients and individuals at elevated hypoglycemia risk. Sitagliptin is approved as monotherapy for type 2 diabetes in patients who cannot use metformin, and as a combination therapy added to metformin, sulfonylureas, PPAR-gamma agonists like pioglitazone, or insulin regimens when additional glycemic control is needed. It is also available in fixed-dose combination tablets with metformin under the brand name Janumet. The magnitude of hemoglobin A1C reduction with sitagliptin monotherapy is modest, typically lowering A1C by approximately 0.5 to 0.8 percentage points. When added to other agents, the incremental reduction follows a similar range. Prescribers considering sitagliptin weigh this modest efficacy against its tolerability profile, which is generally favorable and does not include weight gain as a common side effect. Kidney function is important for sitagliptin dosing. The medication is primarily eliminated by the kidneys, and dose reduction is recommended when estimated glomerular filtration rate falls below established thresholds. Providers check kidney function at baseline and may adjust the dose as kidney function changes over time. Rare but serious adverse events associated with DPP-4 inhibitors include acute pancreatitis, and patients are advised to report persistent severe abdominal pain to their provider promptly. Joint pain and upper respiratory tract infections are the more commonly reported tolerability events in clinical trials. For patients beginning or considering sitagliptin therapy, learning about januvia-sitagliptin for diabetes management provides a clear foundation for informed clinical discussions. For patients exploring the full spectrum of type 2 diabetes agents and how they are selected and combined, the resources at diabetes medication category guides offer comprehensive clinical context.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.